文献速递痛风与晶体性关节病

枸橼酸合剂与碳酸氢钠在苯溴马隆治疗的中国原发性痛风患者中碱化尿液的疗效与安全性:前瞻性随机对照研究

The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该前瞻性随机对照研究纳入200例中国痛风患者,比较枸橼酸合剂(7 g/天)与碳酸氢钠(3 g/天)在苯溴马隆治疗下碱化尿液的疗效与安全性。结果显示两组尿液pH值均较基线显著升高且组间各时间点无显著差异;碳酸氢钠组eGFR显著下降且尿潜血发生率更高,枸橼酸合剂组痛风发作频率更低。

要点

  • 枸橼酸合剂与碳酸氢钠在苯溴马隆治疗下碱化尿液疗效相当,均显著升高尿pH值。
  • 碳酸氢钠组12周后eGFR显著下降,枸橼酸合剂组eGFR与基线相当。
  • 枸橼酸合剂组尿潜血发生率及痛风发作频率均低于碳酸氢钠组。

核心结论

  • 在苯溴马隆治疗下,枸橼酸合剂碱化尿液的疗效与碳酸氢钠相当,且无显著不良事件。
  • 枸橼酸合剂在降低尿潜血发生率和痛风发作频率方面优于碳酸氢钠。

研究设计与样本

  • 前瞻性、随机、平行对照试验,纳入青岛大学附属医院痛风专病门诊的200例痛风患者。
  • 参与者按1:1随机分为碳酸氢钠组(3 g/天)和枸橼酸合剂组(7 g/天)。
  • 所有患者起始接受苯溴马隆25 mg/天,并维持至50 mg/天。
  • 在基线、第2、4、8和12周随访时收集临床和生化数据。

主要发现

  • 共182例患者完成12周尿液碱化研究。
  • 碳酸氢钠组尿pH值从基线5.50升至6.00(P < 0.05),枸橼酸合剂组从5.53升至5.93(P < 0.05)。
  • 两组间各时间点尿pH值比较无显著差异。
  • 碳酸氢钠组12周试验后eGFR显著下降(P < 0.01),枸橼酸合剂组基线至末次随访eGFR相当(P > 0.05)。
  • 碳酸氢钠组尿潜血发生率高于枸橼酸合剂组(38% vs 24%,P < 0.05),肾结石发生率相似。

关键数值与推荐

  • 碳酸氢钠组尿pH值从基线5.50升至6.00(P < 0.05),枸橼酸合剂组从5.53升至5.93(P < 0.05)。
  • 碳酸氢钠组12周后eGFR显著下降(P < 0.01),枸橼酸合剂组基线至末次随访eGFR相当(P > 0.05)。
  • 尿潜血发生率:碳酸氢钠组38% vs 枸橼酸合剂组24%(P < 0.05)。
  • 痛风发作两次的频率:枸橼酸合剂组4% vs 碳酸氢钠组12%(P = 0.037)。

临床怎么用

  • 在苯溴马隆治疗的中国原发性痛风患者中,可考虑使用枸橼酸合剂(7 g/天)替代碳酸氢钠(3 g/天)碱化尿液。
  • 枸橼酸合剂可能有助于减少尿潜血和痛风发作频率,且对eGFR无显著不利影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy and safety of citrate mixture and sodium bicarbonate on urine alkalization in gout patients under benzbromarone treatment. METHODS: A prospective, randomized, parallel controlled trial was conducted among 200 gout patients in the dedicated gout clinic of the Affiliated Hospital of Qingdao University. The participants were randomly divided into two groups (1:1), sodium bicarbonate group (3 g/day) and citrate mixture group (7 g/day). All patients were prescribed with 25 mg/day benzbromarone at initiation and maintained at a dose of 50 mg/day. Clinical and biochemical data were collected at each follow-up time point (baseline, weeks 2, 4, 8 and 12). RESULTS: A total of 182 patients completed the 12-week urine alkalization study. The urine pH value of both groups increased significantly from the baseline to the final follow-up time point (sodium bicarbonate group, 5.50-6.00, P < 0.05; citrate mixture group, 5.53-5.93, P < 0.05). While the comparisons regarding urine pH between treatment groups showed no significant differences for each time point. The estimated glomerular filtration rate (eGFR) dropped significantly after 12 weeks' trial in the sodium bicarbonate group (P < 0.01), while it was comparable between baseline and the last follow-up (P > 0.05) in the citrate mixture group. Results of urine analysis showed that the incident rate of occult blood in the sodium bicarbonate group was higher than that in the citrate mixture group (38 vs 24%, P < 0.05), accompanied by a similar occurrence of kidney stones. After 12-week follow-up, the frequency of twice gout flare in the citrate mixture group was significantly lower than that in sodium bicarbonate group (4 vs 12%, P = 0.037). No treatment-emergent adverse events occurred. CONCLUSION: The efficacy of citrate mixture on urine alkalization is comparable to sodium bicarbonate under benzbromarone treatment without significant adverse events. Citrate mixture is superior to sodium bicarbonate in lowering the incidence of urine occult blood and the frequency of gout attacks. TRIAL REGISTRATION: Registered with ChiCTR (http://www.chictr.org.cn), No. ChiCTR1800018518.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Xue X, Liu Z, Li X, et al. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study. Rheumatology (Oxford). 2021. PMID: 33211886. doi:10.1093/rheumatology/keaa668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。